The $25,000 Member Problem: How GLP-1 Coverage Is Reshaping Specific Deductible Calculations
Specific deductibles exist to protect self-funded employers from catastrophic individual claims. The actuarial logic is straightforward: most members have predictable costs; a few outliers generate extreme claims; specific stop-loss reinsures those outliers above a defined threshold.
GLP-1 drugs are not catastrophic claims in the traditional sense. A member on Wegovy or Zepbound for a full plan year won’t hit a $150,000 specific deductible on drug spend alone. But they will generate $15,000 to $25,000 in annual pharmacy costs — predictably, persistently, and in growing numbers.
The problem this creates for specific deductible design isn’t about the individual claim. It’s about what happens when 4%, 6%, or 8% of a group’s covered lives are on these medications simultaneously — and your attachment point was set based on experience data from before that adoption curve.
What ‘Expected Claims’ Looks Like Now
The traditional model for setting specific deductible levels is built around expected claims — a projection of what the group will cost based on prior year experience, adjusted for trend. For most groups, medical trend runs 7–9% annually. For groups with meaningful GLP-1 exposure, pharmacy trend is running 11–12% or higher.
When you blend those two trends, the average looks manageable. But the distribution of claims shifts. More members are generating $10,000–$30,000 in pharmacy costs. Fewer members are generating zero pharmacy costs. The tail gets fatter at both ends.
A specific deductible set at 125% of single expected claims for a group with 5% GLP-1 utilisation may now be underpriced relative to actual risk. The same attachment point that provided adequate protection two years ago may now be meaningfully exposed.
11–12%
Projected pharmacy cost trend for employer-sponsored plans in 2026 — vs 8.5% medical trend. The gap is widening every quarter.
The Attachment Point Recalibration Question
There are two levers underwriters typically use to respond to elevated expected claims: raise the specific deductible (shift more risk back to the employer) or raise the specific premium (keep the attachment point but charge more for the increased exposure). For GLP-1 risk, both responses have merit and both have limits.
Raising the specific deductible on a group with high GLP-1 exposure effectively prices that employer out of self-funding’s cost advantage. If the attachment point moves from $75,000 to $110,000 to account for pharmacy trend, the employer’s self-funded risk profile changes materially. Some will move back to fully insured alternatives. That’s not always a bad outcome for a carrier, but it’s a pricing outcome that should be intentional, not accidental.
The more defensible approach is to adjust specific rates based on a systematic GLP-1 loading factor, applied at the member level where possible. A group where two members are known to be on high-cost GLP-1 therapy can be rated with a per-member adjustment that reflects actual exposure — not a blanket deductible increase that penalises the whole group.
Why This Requires a Rules Engine, Not a Spreadsheet
The challenge with member-level GLP-1 adjustment is consistency. If the adjustment is made manually by individual underwriters, you get variation. One underwriter applies a $8,000 loading per GLP-1 member. Another uses $12,000. A third doesn’t apply any adjustment because the member’s GLP-1 use wasn’t flagged in the submitted data.
This is exactly the scenario where a configurable rules engine produces better outcomes than manual review. Define the GLP-1 loading factor once — based on your actuarial team’s analysis — and apply it automatically to every submission where GLP-1 exposure is identified. The result is consistent pricing, defensible governance, and faster turnaround.
The secondary benefit is auditability. When a regulator or reinsurer asks why Group X was rated differently than Group Y, a rules-based system produces a traceable answer. Manual adjustments in spreadsheets often cannot.
A Framework for GLP-1 Adjustment in Specific Deductible Pricing
Step 1: Ask explicitly at submission whether the group covers GLP-1 drugs for weight loss (not just diabetes). Many brokers won’t volunteer this.
Step 2: Request a 12-month pharmacy claims extract or at minimum a list of specialty drug utilisation. GLP-1 costs are identifiable in NDC code data.
Step 3: Apply a tiered loading factor based on the number of GLP-1 users relative to covered lives: 0–2% utilisation = standard rating; 2–5% = moderate load; >5% = elevated load with potential lasering review.
Step 4: Document the adjustment in your rating file. If the group renews next year, you need the baseline.
Step 5: Build in a mid-year review trigger. If pharmacy trend significantly outpaces projection at the 6-month claims review, flag for potential deductible renegotiation at renewal.
The Broader Point
GLP-1 is the clearest signal of a broader shift already underway: specialty drugs aren’t just increasing total claims, they’re reshaping the distribution itself. The average still appears stable enough to pass a high-level review, but the underlying risk is spreading — more members consistently sitting in high-cost bands, and more groups experiencing sudden adoption spikes that weren’t reflected in prior experience. That’s where stop-loss carriers are getting caught off guard.
Specific deductible strategy has always been built around protecting against outliers, but the definition of an outlier is evolving from rare, catastrophic events to repeatable, high-cost patterns that exist just below the attachment point. Pricing this accurately requires more than adjusting assumptions — it requires consistently identifying where that exposure exists in the first place and applying a uniform response to it.
DataHub addresses this at both stages: SmartExtractor™ automatically surfaces GLP-1 and broader specialty drug utilization directly from submitted census and pharmacy data, ensuring that exposure is visible at the start of underwriting rather than discovered late or missed entirely, and SmartRules™ Engine translates that visibility into action by applying predefined, actuarially aligned loading logic at the member level during rating. The result is not just better pricing, but more reliable pricing — where similar risk profiles are treated consistently, adoption-driven shifts are accounted for systematically, and underwriters can adapt to a changing definition of “outlier” without relying on manual judgment or fragmented workflows.
If you’re evaluating how GLP-1 exposure is handled in your current underwriting process, start with a structured approach. Download the GLP-1 underwriting checklist to see what should be captred, adjusted, and documented at every stage of rating.
And if you want to see how this works in practice without relying on spreadsheets or manual review – book a walkthrough and see how teams are applying these adjustments automatically within DataHub.